Mainstay Medical, a Dublin-based medtech company, has successfully raised US$125 million in an equity financing round, as announced by fhpartners and SofinnovaVC. The funds are earmarked for the commercial expansion of ReActiv8, their innovative neurostimulation therapy designed to treat chronic lower back pain. This significant financial boost, supported by GildeHealthcare among others, was highlighted by several entities, underscoring the potential impact of ReActiv8 on the chronic lower back pain market. The therapy represents a major advancement in neuromodulation treatments, offering hope to those suffering from this debilitating condition.
Dublin-based Mainstay Medical raises $125m for back pain product https://t.co/CXG70VmamX via @siliconrepublic
#MustRead: Irish medtech company @MainstayMedical has raised $125m in an equity financing round to fund the commercial expansion of its flagship back pain product. https://t.co/mxEtjSNkCT
Irish back pain group Mainstay Medical raises €115m to fund expansion https://t.co/DKyfdvrAeF
🚀 Excited to announce our portfolio @MainstayMedical has secured $125M in equity financing for their innovative ReActiv8 Neurostimulation therapy for #chroniclowerbackpain. A major step forward! #VC #innovation #biotech https://t.co/CQMAK0PyOd @GildeHealthcare @fhpartners #VC https://t.co/CS3NrCAtVM
Pharmacy startup Zeno Health raises $25 million in funding round led by STIC Investments The latest capital infusion will help expand its consumer base and footprint, and further enhance its technological infrastructure. By: @supriya_speaks https://t.co/yDGceu1I3r
Irish medtech company @MainstayMedical has raised $125m in an equity financing round to fund the commercial expansion of its flagship back pain product. https://t.co/mxEtjSNkCT
Take a look at today's Daily Brief for the latest sci-tech news, such as: 🤖 Microsoft invests in Mistral AI 💰 Dublin’s @MainstayMedical raises $125m 🔬 How @UCC researchers revealed a fake fossil ...and more! https://t.co/G46d14pTMX
Dublin-based Mainstay Medical raises $125m for back pain product https://t.co/mxEtjSNkCT
🚀 Excited to announce our portfolio @mainstaymedica has secured $125M in equity financing for their innovative ReActiv8 Neurostimulation therapy for #chroniclowerbackpain. A major step forward! #VC #innovation #biotech https://t.co/0A2PXpeEmG @GildeHealthcare @fhpartners https://t.co/2pF23qK59i
Mainstay Medical Announces US$125 Million Equity Financing Transaction to further commercialization of ReActiv8 for chronic lower back pain. #chroniclowerbackpain #neuromodulation https://t.co/OzQg9G7jfB